Alzheimer’s Disease/Dementia News

Persistent higher or moderate-to-increasing inflammation that begins in early adulthood may result in worsening midlife executive function and processing speed, according to data published in Neurology.

The FDA approved Kisunla for adults with early symptomatic Alzheimer’s disease, including those with mild cognitive impairment and mild dementia with confirmed amyloid pathology.

A self-administered assessment tool was effective in identifying cognitive impairment vs. routine care in primary care settings, according to results recently published in Frontiers in Medicine.

In a phase 2/3 clinical trial, treatment with buntanetap was linked to cognitive gains as well as tau reduction at 12 weeks in those exhibiting mild to moderate symptoms of Alzheimer’s disease, according to the drug’s manufacturer.

An FDA advisory panel on Monday voted in favor of donanemab as a treatment for early symptomatic Alzheimer’s disease.

Endovascular therapy was linked with improved outcomes across five cognitive tests in those with acute ischemic stroke, according to research published in Neurology.

The Alzheimer’s Drug Discovery Foundation has invested $5 million in Coya Therapeutics to help accelerate development and advance drugs to prevent, treat and cure Alzheimer’s disease and related dementias.

Women diagnosed with preeclampsia were 2.6 times more likely to develop early-onset dementia during 9 years of follow-up compared with women who did not have a hypertensive disorder of pregnancy, according to registry data.

Otsuka Pharmaceutical has terminated its development of AVP-786, a novel compound that was being researched as a potential treatment for patients with agitation due to Alzheimer’s disease, according to a company-issued press release.

Alzheon Inc. has enrolled patients who completed either phase 2 or phase 3 trials to evaluate ALZ-801 as a treatment for early Alzheimer’s disease in long-term study extensions, according to a company-issued press release.